Zetagen Therapeutics Announces Oversubscribed $12.9M Series B1 Financing to Advance Breakthrough Intratumoral Therapies for Breast Cancer Zetagen Therapeutics, Inc., a privately held clinical-stage biopharmaceutical company advancing first-in-class intratumoral therapies for…
Enigma Biomedical USA Awarded $2 Million Grant from The Michael J. Fox Foundation to Advance Novel α-Synuclein PET Imaging Biomarker for Parkinson’s Disease Enigma Biomedical USA (EB USA) today announced…
Vyome Holdings Announces Appointment of Renowned Oncologist Dr. Aditya Bardia as Senior Medical Advisor to Advance VT-1953 for Malignant Fungating Wounds Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage healthcare…
Pathway to Cures Invests in SeraGene Therapeutics The fifth paragraph of the original release dated November 19, 2025, should read: Pathway to Cures joins Hextwo Capital as early investors in…
CareDx Announces Publication of New SHORE Study Demonstrating the Prognostic Power of HeartCare® for Heart Transplant Recipients in the Journal of Heart and Lung Transplantation CareDx, Inc. (Nasdaq: CDNA), a…
Kelonia Therapeutics Announces Late-Breaking Oral Presentation Showcasing First-in-Human Data for KLN-1010, an In Vivo BCMA CAR-T Gene Therapy, at ASH 2025 Kelonia Therapeutics, Inc., a clinical-stage biotechnology company advancing a…
Microsize and Schedio Group Sign Agreement to Acquire Lonza’s Micro-Macinazione Facility in Switzerland, Advancing a Transatlantic Particle Engineering Platform Microsize, a prominent contract development and manufacturing organization (CDMO) known for…
AstraZeneca Announces $2 Billion Expansion to Strengthen Maryland Manufacturing, Advance Innovation, and Support 2,600 Jobs AstraZeneca today unveiled a major strategic investment plan totaling $2 billion to expand its long-standing…
FDA Authorizes PADCEV® + Keytruda® Regimen for Eligible Individuals with Bladder Cancer Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503; President and CEO: Naoki Okamura, “Astellas”) announced that…
Parabilis Medicines Announces Compelling Preliminary Clinical Results for FOG-001 in Adamantinomatous Craniopharyngioma at SNO 2025 Parabilis Medicines, a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients with cancer,…
Blue Lake Biotechnology Announces FDA Clearance to Resume Enrollment of RSV-Negative and Younger Toddlers in Phase 1/2a Clinical Trial of BLB201 Blue Lake Biotechnology, Inc., a clinical-stage company pioneering intranasal…
AGC Biologics and AAVantgarde Forge New Manufacturing Partnership to Advance Dual-Vector Gene Therapies for Inherited Retinal Diseases Following AAVantgarde Bio’s recent completion of a successful Series B financing round, the…
